Pharsight

Drugs that contain Methotrexate

1. Jylamvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11771701 SHORLA Methotrexate formulation
Oct, 2034

(10 years from now)

US11129833 SHORLA Methotrexate formulation
Oct, 2035

(11 years from now)

Market Authorisation Date: 29 November, 2022

Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate

Dosage: SOLUTION;ORAL

More Information on Dosage

JYLAMVO family patents

Family Patents

2. Otrexup patents expiration

OTREXUP's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776015 OTTER PHARMS Needle assisted jet injector
Aug, 2019

(4 years ago)

USRE44846 OTTER PHARMS Needle assisted jet injector
Aug, 2019

(4 years ago)

USRE44847 OTTER PHARMS Needle assisted jet injector
Aug, 2019

(4 years ago)

US7744582 OTTER PHARMS Needle assisted jet injector
Aug, 2019

(4 years ago)

US6746429 OTTER PHARMS Needle assisted jet injector
Apr, 2020

(4 years ago)

US9629959 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(1 year, 8 months from now)

US8562564 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(1 year, 8 months from now)

US9533102 OTTER PHARMS Prefilled syringe jet injector
Jan, 2026

(1 year, 8 months from now)

US11446441 OTTER PHARMS Prefilled syringe injector
Jan, 2026

(1 year, 8 months from now)

US8021335 OTTER PHARMS Prefilled syringe jet injector
Oct, 2026

(2 years from now)

US11684723 OTTER PHARMS Injector safety device
Mar, 2029

(4 years from now)

US10709844 OTTER PHARMS Injector safety device
Mar, 2029

(4 years from now)

US9867949 OTTER PHARMS Injector safety device
Mar, 2029

(4 years from now)

US8579865 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(5 years from now)

US8480631 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(5 years from now)

US8945063 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(5 years from now)

US11497753 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(5 years from now)

US9421333 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(5 years from now)

US8814834 OTTER PHARMS Injector safety device
May, 2031

(7 years from now)

Market Authorisation Date: 07 November, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

OTREXUP family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Rasuvo patents expiration

RASUVO's oppositions filed in EPO
RASUVO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8664231 MEDEXUS Concentrated methotrexate solutions
Jun, 2029

(5 years from now)

Market Authorisation Date: 10 July, 2014

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

RASUVO family patents

Family Patents